CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 44 enrolled
Drug / intervention
Cediranib Maleate +3 moredrug
Likely dose
Cediranib dose not specified in interventions or study design sectionsAI-extracted
Key inclusion· 6
  • ✓Histologically or cytologically confirmed renal cell cancer that is locally recurrent or metastatic and not curable by standard therapy
  • ✓Measurable disease: at least one lesion >20 mm on conventional imaging or >10 mm on spiral CT; all radiology within 28 days of registration
  • ✓ECOG performance status ≤2 (Karnofsky ≥60%)
  • ✓Life expectancy >3 months
Key exclusion· 12
  • ✕Prior systemic chemotherapy
  • ✕Prior immunotherapy
  • ✕Prior gene or investigational therapy
  • ✕Known brain metastases

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00227760
NCT00227760Phase 2Completed
CompareCT.gov

A Phase 2 Study of AZD2171 in Progressive Unresectable, Recurrent or Metastatic Renal Cell Carcinoma (RCC)

National Cancer Institute (NCI)·interventional·Posted Sep 28, 2005·Updated Feb 29, 2016

In Brief

A Phase 2 clinical trial evaluating Cediranib Maleate, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, and 2 other interventions for Recurrent Renal Cell Carcinoma and Stage IV Renal Cell Cancer. Completed, enrolled 44 participants across 6 sites.

Detailed Summary

This phase II trial studies how well cediranib maleate works in treating patients with recurrent or metastatic kidney cancer that cannot be removed by surgery. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer
CountriesCanada
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 28, 2005
Enrollment StartDec 1, 2005
Primary CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 7.4 yearsPosted 20.8 years ago

Interventions

Cediranib Maleatedrug

Given PO

Dynamic Contrast-Enhanced Magnetic Resonance Imagingprocedure

Correlative studies

Laboratory Biomarker Analysisother

Correlative studies

Pharmacological Studyother

Correlative studies